Dr. MiltieAtlas by Dr. Miltie™Healthcare Grant Intelligence
ActiveAtlas Opportunity Score 86/100
BPM007621Arizona

Arizona Department of Health Services Second-Tier Testing and Pre-Symptomatic Detection of Cystic Fibrosis — BPM007621

FundingFixed-price state-funded procurement; no fixed ceiling stated; ADHS does not guarantee volume and authorizes work by purchase order
DeadlineSeptember 24, 2026 at 3:00:00 PM Local Arizona Time
Last verifiedSeptember 16, 2026
Required next actionQualified CFTR assay and reagent-rental vendors should review the live APP record and amendments before submitting. No Dr. Miltie, N9+, or QC Healthcare capture is prioritized because the required laboratory capability is not established.

Broad Eligibility

Vendors capable of providing the specified FDA-cleared or FDA-approved CFTR assay reagent-rental solution and satisfying all solicitation licensing, technical, contractual, APP form, insurance, and Business Associate Agreement requirements.

Atlas Analysis

Atlas Opportunity Score 86/100. Healthcare-scope gate: PASS. The controlling Arizona procurement directly supports newborn screening and pre-symptomatic detection of cystic fibrosis through specialized CFTR genotyping laboratory equipment, reagents, and support. N9+ Fit 0/100 and QC Healthcare Fit 0/100 reflect product/vendor mismatch only and do not negate the direct clinical/public-health screening nexus. Dr. Miltie direct-vendor fit 0/100.

Open now. The Arizona Department of Health Services, through the Arizona State Public Health Laboratory Newborn Screening Program, is soliciting bids under BPM007621, Second-Tier Testing and Pre-Symptomatic Detection of Cystic Fibrosis. The official IFB Notice Page sets bids due September 24, 2026 at 3:00:00 PM Local Arizona Time through the State of Arizona Procurement Portal (APP).

Scope: a complete reagent-rental solution for an FDA-cleared or FDA-approved DNA-based cystic fibrosis assay system, identified as xTAG Cystic Fibrosis (CFTR) 60 Kit v2 US IVD or equivalent, operating on the Luminex 200 System with xPONENT 3.1 or an equivalent platform. Minimum specifications include simultaneous detection of at least 60 CFTR variants including the 23 ACMG/ACOG variants, batch runtime no more than eight hours for at least 96 specimens, plus instrumentation, reagents, consumables, software, maintenance, repairs, loaner or replacement support, training, validation assistance, warranty, and technical support.

Vendor requirements and forms: contractors must maintain required federal, state, and local licenses and permits. The official APP Technical Questionnaire requires Offer and Acceptance, Notices Correspondence and Payments, Proposed Subcontractors, and a Business Associate Agreement. Proposed subcontracts require advance written approval. A valid certificate of insurance is required within five days after contract award.

Contract structure: fixed price and state funded, with a one-year initial term and successive 12-month extensions up to a five-year aggregate maximum. ADHS does not guarantee volume. Work is authorized by purchase orders. The solicitation does not state a fixed contract ceiling.

Atlas Opportunity Score: 86/100. This is a highly specific Arizona newborn screening and laboratory procurement. N9+ Fit: 0/100. QC Healthcare Fit: 0/100. Dr. Miltie direct-vendor fit: 0/100. The verified requirement is CFTR genotyping laboratory instrumentation, reagents, and associated support, not telehealth, remote physical examination, RPM, CCM, TCM, or an established QC Healthcare capability. No fit is forced.

Procurement contact: Ryan Garcia, Procurement Officer, Arizona Department of Health Services, ryan.garcia@azdhs.gov, (480) 617-5338. Vendors should use the live APP record to check amendments before responding.

Official source: State of Arizona Procurement Portal, BPM007621.

Source verificationOfficial government source · app.az.govAtlas last verified this record September 16, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗